The addition of Biodesix’s Nodify Lung nodule risk assessment tool to Philips’ lung cancer patient management system may enhance diagnostic efficiency and facilitate improved management of high-risk patients.
In the ongoing quest to expedite timely intervention for patients with lung cancer and rein in the amount of biopsies on benign nodules, Philips has added Nodify Lung (Biodesix), a blood-based risk assessment tool for lung nodules, to the company’s Lung Cancer Orchestrator system.
Philips said the Nodify Lung testing detects the presence of blood-based biomarkers and provides proteomic data that may provide adjunctive value to clinical and radiomic assessment in the classification of malignancy risk.
“By incorporating Biodesix’s Nodify Lung testing, we take another step in leveraging integrated diagnostics from imaging, genomics, and now proteomic results from a simple blood draw to address key moments in the lung cancer patient journey, support care team decision-making, and help health systems learn from their practice patterns in a dashboard view,” said Louis Culot, the general manager of oncology informatics and genomics at Philips.
“We are delighted that our tests are being incorporated into Philips’ vision for end-to-end cancer care management using a multi-diagnostic approach,” said Scott Hutton, the president and chief executive officer at Biodesix. “By integrating our Nodify® tests in Philips Lung Cancer Orchestrator, we hope to make these tests more accessible to physicians and patients and more easily utilized by care teams with the ultimate goal of improving patient care and outcomes.”
Philips said the Lung Cancer Orchestrator, an integrated patient management system that can be utilized for computed tomography (CT) lung cancer screening programs as well as incidental findings of lung nodules, enables physicians to keep track of imaging findings, appointments, and clinical decisions.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.